Capital Impact Advisors, LLC Arcus Biosciences, Inc. Transaction History

Capital Impact Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$17.62 - $23.54 $42,481 - $56,754	2,411 Added 11.02%	24,280 $435,000
Q2 2023 Aug 14, 2023	BUY	$16.97 - $22.03 $23,214 - $30,137	1,368 Added 6.67%	21,869 $444,000
Q1 2023 May 23, 2023	BUY	$15.96 - $23.15 $69,330 - $100,563	4,344 Added 26.89%	20,501 $373,000
Q4 2022 Feb 14, 2023	BUY	$19.7 - $35.71 $152,812 - $277,002	7,757 Added 92.35%	16,157 $334,000
Q3 2022 Nov 21, 2022	BUY	$23.23 - $30.07 $7,689 - $9,953	331 Added 4.1%	8,400 $241,000
Q2 2022 Aug 15, 2022	BUY	$17.23 - $37.73 $139,028 - $304,443	8,069 New	8,069 $204,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Capital Impact Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Capital Impact Advisors, LLC with notifications on news.